Eli Lilly has introduced higher doses of its weight loss drug Zepbound in single-dose vials at significantly reduced prices to improve access for patients without insurance coverage, including those on Medicare. This move aims to meet soaring demand and ensure eligible patients receive safe and effective treatment instead of cheaper compounded alternatives. The company is offering 7.5 milligram and 10 milligram vials of Zepbound for $499 per month for initial prescriptions and refills within 45 days, with prices rising to $599 and $699 respectively if purchased later. Additionally, Eli Lilly has reduced the price of lower-dose vials by $50, with the 2.5 milligram vial now priced at $349 and the 5 milligram vial at $499. These vials, which require patients to self-administer using a syringe, are easier to manufacture than autoinjector pens, potentially increasing supply. The pricing strategy benefits uninsured patients and those in Medicare or employer-sponsored plans that do not cover obesity treatments. Eli Lilly’s Patrik Jonsson emphasized the need for affordable solutions, particularly for the Medicare population, amid limited insurance coverage for obesity medications. The company hopes for policy changes to include Medicare coverage for such treatments. Meanwhile, the FDA has declared an end to the Zepbound shortage, which may restrict compounding pharmacies from producing unapproved versions. Jonsson stated that Eli Lilly is focused on ensuring patients use FDA-approved treatments for safety and efficacy. — news from CNBC
